Additionally, the PD-L1 inhibitor pembrolizumab has been sanctioned as a highly effective therapeutic option for patients with PD-L1-positive or advanced esophageal squamous cell carcinoma (ESCC) (31, 32). This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.